Cargando…
Retrospective Database Analysis to Explore Patterns and Economic Burden of Switchback to Brand After Generic or Authorized Generic Utilization
BACKGROUND: Despite demonstration of bioequivalence of generics to brands and the potential for reduced costs, some patients switch back from a generic to the brand. A prior retrospective analysis suggested that this switchback rate may be lower among patients that had initially switched to authoriz...
Autores principales: | Alderfer, Justine, Aggarwal, Jyoti, Gilchrist, Kim, Alvir, Jose Maria Jimenez, Cook, Joseph, Park, Sang Hee, Stephens, Jennifer M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9059206/ https://www.ncbi.nlm.nih.gov/pubmed/35509961 http://dx.doi.org/10.2147/CEOR.S319796 |
Ejemplares similares
-
Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study
por: Desai, Rishi J, et al.
Publicado: (2018) -
Brand and generic medications: Are they interchangeable?
por: Al-Jazairi, Abdulrazaq S., et al.
Publicado: (2008) -
Prescription writing: Generic or brand?
por: Andrade, Chittaranjan, et al.
Publicado: (2017) -
Brand Name Versus Generic?
por: Aungaroon, Gewalin
Publicado: (2023) -
Potential Clinical and Economic Impact of Switching Branded Medications to Generics
por: Straka, Robert J., et al.
Publicado: (2017)